Hypofibrinolysis: A common, major cause of osteonecrosis
- 1 February 1994
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 45 (2) , 156-166
- https://doi.org/10.1002/ajh.2830450212
Abstract
In 30 patients with osteonecrosis of the hip (12 idiopathic, 18 secondary), we assessed the role of hypofibrinolysis mediated by high levels of piasminogen activator inhibitor (PAI). We evaluated hypofibrinoiysis as a common, potentially reversible, pathophysiologic cause of idiopathic osteonecrosis. In all 18 patients with secondary osteonecrosis. PAI was normal, as was the ability to activate fibrinoiysis. Nine of the 12 patients with idiopathic osteonecrosis had exceptionally high PA1 levels and could not normally elevate tissue piasminogen activator (tPA-Fx), the major stimulator of fibrinolysis, after 10 min of venous occlusion at 100 mm Hg. The group of 12 patients with idiopathic osteonecrosis, compared to the 18 with secondary osteonecrosis, had low mean stimulated tPA-Fx (1.92 vs. 7.6 IU/mi, P .001) and very high stimulated PAI-Fx (70 vs. 7.6 U/mi, P ⩽ .01). Three of the 12 patients with idiopathic osteonecrosis had both normal PAI and normal Stimulated tPA-Fx. These three patients and 14 of the 18 with secondary osteonecrosis had high lipoprotein (a) [Lp(a)] (>20 mg/dI). Mean Lp(a) was much higher (60 mg/dI) in the patients with secondary osteonecrosis than Lp(a) (16 mg/dI, P ⩽ .001) in the 12 patients with idiopathic osteonecrosis. These findings suggest that hypofibrinoiysis mediated by high PAI is a common cause of idiopathic osteonecrosis, whereas high Lp(a) may play an etiologic role in secondary osteonecrosis. Prospective studies of patients with high PA1 and/or high Lp(a) should be carried out to assess further their apparently causal roles in osteonecrosis.Keywords
This publication has 39 references indexed in Scilit:
- NIH Consensus conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart DiseasePublished by American Medical Association (AMA) ,1993
- Lipoprotein(a) inhibits plasminogen activation in a template-dependent mannerBlood Coagulation & Fibrinolysis, 1991
- The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic DiseaseSeminars in Thrombosis and Hemostasis, 1990
- Lipoprotein (a). Heterogeneity and biological relevance.Journal of Clinical Investigation, 1990
- The increased plasma Lp(a) : B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysisClinica Chimica Acta; International Journal of Clinical Chemistry, 1990
- A Microangiographic Study of Idiopathic Osteonecrosis of the Femoral HeadPublished by Wolters Kluwer Health ,1989
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987
- Increased concentration of the fast‐acting plasminogen activator inhibitor in plasma associated with familial venous thrombosisBritish Journal of Haematology, 1987
- An analysis of variance test for normality (complete samples)Biometrika, 1965
- Severe Thrombotic Disease in a Young Man with Bone Marrow and Skeletal Changes and with a High Content of an Inhibitor in the Fibrinolytic SystemActa Medica Scandinavica, 1961